CACeylan Ayada

Ceylan Ayada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ceylan Ayada has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the Knowledge, Attitudes, and Behaviors of Antibiotics Usage at the Parents Living in the Aegean Part of Turkey

    by Yasemin Korkut, Alime Emre, Ceylan Ayada

    Objective: Antibiotics are considered to be one of the greatest discoveries of the 20th century. The widespread and inappropriate use of antibiotics leads to resistance to microorganisms, increased cost, and at the same time an increase in the incidence of secondary side effects. We aimed to determine the knowledge, attitudes, and behaviors about the use of antibiotics of the parents living in the Aegean part of Turkey.Methods: The study was conducted with parents of 252 children who applied to the Kutahya Family Health Center between May and October 2017. The data were collected by face-to-face interview using a questionnaire survey prepared by the investigator. Descriptive and categorical statistics were used for the study. Categorical variables were compared using the Chi-square test. The level of statistical significance was set at p<0.05. Results: The mean age of parents was 32.83 ± 7.61 years and most of them were in a low education and income group. There was negative correlation between education level and use of correct antibiotics (p<0.01). This sentence given by you is like a interpretation and should be in a conclusion or discussion. Additionally, the correct level of knowledge of parents living in the urban area, male gender, and unemployed was determined to be lower. Conclusions: Rational antibiotic use is an important health issue in our country. We anticipate regional differences in evaluations of antibiotic use and we believe that, in order to increase the efficiency of antibiotic use, it is necessary to increase the level of education in the region and to reprogram health education to the public. Family Doctors should be sensitive to the use of antibiotics and inform the patient during the interview process. We believe that guidance and strategy can be developed for the national-international correct use of antibiotics using these regional data that we have obtained.


  • High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients

    by M. Acat, U. Toru Erbay, S. Sahin, O. Arik, C. Ayada

    High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients


  • Possible Activation of the Immune System by Chronic Peripheral Nesfatin-1 Application at the Acute Phase of Ischemia/Reperfusion Injury

    by Umran Toru, Ceylan Ayada, Osman Genc, Raziye Akcilar, Server Sahin, Gulten Erken, Haydar Ali Erken, Gunfer Turgut, Sebahat Turgut


  • Evaluation of Serum Levels of Renin Angiotensin System Components in Asthmatic Patients

    by Ceylan Ayada, Umran Toru, Osman Genc, Server Sahin, Ismet Bulut, Ozlem Arik, Murat Acat


    • 6 October 2015
      • Vol. 19  (1) , 4-10

    Nesfatin-1 and its effects on different systems.

    by C Ayada, Ü Toru, Y Korkut

    Nesfatin-1 is a peptide secreted by peripheral tissues, central and peripheral nervous system. It is involved in the regulation of energy homeostasis related with food regulation and water intake. Nesfatin-1 can pass through the blood-brain barrier in both directions. It suppresses feeding independently from the leptin pathway and increases insulin secretion from pancreatic beta islet cells. That is why nesfatin-1 has drawn attention as a new therapeutic agent, especially for the treatment of obesity and diabetes mellitus. Its effects on nutrition have been studied in more detail in literature. On the other hand, its effects on other physiological parameters and mechanisms of action still need to be clarified. Synthesizing the research on nesfatin-1 can help us better understand this field. Hippokratia 2015, 19 (1): 4-10.


  • Open Access

    Evaluation of multidrug resistance-1 gene C>T polymorphism frequency in patients with asthma

    by Ümran Toru, Ceylan Ayada, Osman Genç, Zehra Yaşar, Server Şahin, Emre Taşkın, İsMet Bulut, Murat Acat

    Asthma is a chronic inflammatory lung disease characterized by bronchial hyperresponsiveness and airflow obstruction. Genetic and oxidative stress factors, in addition to pulmonary and systemic inflammatory processes, play a pivotal role in the pathogenesis of asthma. The products of the multidrug resistance-1 gene protect lung tissue from oxidative stress. Here, we aimed to evaluate the association between the multidrug resistance-1 gene C>T polymorphism and asthma with regard to oxidative stress-related parameters of asthmatic patients. Forty-five patients with asthma and 27 healthy age-matched controls were included in this study. Blood samples were collected in tubes with ethylenediaminetetraacetic acid. DNA was extracted from the blood samples. The multidrug resistance-1 gene polymorphism was detected by polymerase chain reaction and a subsequent enzyme digestion technique. The serum levels of total oxidant status and total antioxidant status were determined by the colorimetric measurement method. The heterozygous polymorphic genotype was the most frequent in both groups. A significant difference in the multidrug resistance-1 genotype frequencies between groups indicated an association of asthma with the TT genotype. A significant difference between groups was found for wild type homozygous participants and carriers of polymorphic allele participants. The frequency of the T allele was significantly higher in asthmatic patients. The increase in the oxidative stress index parameter was significant in the asthma group compared with the control group. The multidrug resistance-1 gene C/T polymorphism may be an underlying genetic risk factor for the development of asthma via oxidant-antioxidant imbalance, leading to increased oxidative stress.


  • Serum levels of leptin and visfatin in chronic obstructive pulmonary disease

    by Ceylan Ayada, Ümran Toru, Osman Genç, Server Sahin, Özlem Arik, Ismet Bulut

    Introduction: Chronic obstructive pulmonary disease (COPD) is a lung disorder characterized by airway inflammation and irreversible airflow obstruction. Leptin is secreted by adipose tissue and known as a regulatory factor of food intake and energy homeostasis. Its receptor which provides its specific functions is presented in the lung. It was shown that increased serum leptin level is related with the local inflammatory response in COPD. Visfatin is a pro-inflammatory cytokine which plays a role in the regulation of inflammation. Visfatin is presented as a novel factor associated with systemic inflammation in COPD. The association between systemic or airway leptin or visfatin and COPD is remained controversial. For this reason, we aimed to evaluate serum levels of leptin and visfatin in patients with COPD. Materials&Methods: 27 COPD patients and 16 healthy controls were involved in our study. Blood samples were collected in tubes without EDTA. Serum levels of leptin and visfatin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program. Results: Serum level of leptin was detected as 100.18 ± 16.49 pg/ml in the COPD and 140.43 ± 17.21 pg/ml in the control group. Serum level of visfatin was found as 0.08 ± 0.01 pg/ml in the COPD and 0.06 ± 0.01 pg/ml in the control group. Serum levels of leptin and visfatin were not significantly changed in the COPD group compared to control (respectively; p = 0.053, p = 0.062). Conclusion: According to our results we can conclude that leptin and visfatin may be controlled physiologically under COPD conditions. On the other hand serum level of leptin and visfatinin COPD patients may be related with genetic polymorphic focus.


  • Increased serum level of apelin in chronic obstructive pulmonary disease

    by Ceylan Ayada, Ümran Toru, Osman Genç, Server Sahin, Özlem Arik, Ismet Bulut

    Rationale: Chronic obstructive pulmonary disease (COPD) is described as an abnormal inflammatory response of the lung parenchyma to inhaled irritants and toxins. Apelin is secreted by adipose tissue and endothelial cells but its role in inflammatory processes is not certain. Additionally, it is known that apelin induces apoptosis and suppresses proliferation of human pulmonary arterial smooth muscle cells. Apelin injection can improve right ventricular function in pulmonary hypertension induced rats. A serum level of apelin in COPD is not determined yet. Thus, we aimed to evaluate serum level of apelin in COPD to have clues about the pathophysiology of this disease. Methods: 27 COPD patients and 16 healthy controls were involved in this study. Blood samples were collected in tubes without EDTA. Serum level of apelin was measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program. All data are given as mean ± standard error of the mean (SE). Differences were considered significant at P < 0.05. Results: Serum level of apelin was detected as 65.48 ± 6.3 pg/ml in the COPD and 36.22 ± 3.1 pg/ml in the control group. Serum level of apelin was significantly higher in COPD group compared to the control group (p = 0.003). Conclusion: According to our results we can conclude that apelin may play a role in the development of COPD and maybe a future target as a biomarker for COPD. Additionally, understanding the role of apelin in COPD can help us to develop new treatment strategies. However, further studies are needed to understand the certain role of apelin in the pathophysiology of COPD.

  • Effects of ukrain in rats with intestinal ischemia and reperfusion

    by Raziye Akcilar, Aydın Akcilar, Bircan Savran, Ceylan Ayada, Cengiz Koçak, F. Emel Koçak, Osman Genç


    • 15 April 2015
      • Vol. 8  (4) , 6257-61

    Visfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma?

    by Ümran Toru, Ceylan Ayada, Osman Genç, Server Şahin, Özlem Arık, Murat Acat, Ismet Bulut, Erdoğan Çetinkaya

    Asthma represents chronic inflammation of the airways and is associated with bronchial hyperresponsiveness and reversible airway obstruction. A novel adipokine visfatin and an appetite-modulating hormone ghrelin play a role in several diseases related with inflammation. Although visfatin is a pro-inflammatory adipokine, ghrelin mainly exerts anti-inflammatory effects. However, very little is known about the role of visfatin and ghrelin in asthma. In the present study, we aimed to investigate the role of visfatin and ghrelin in asthma by evaluating their serum levels in asthmatic patients. This study was performed on 27 asthma and 23 healthy controls. Blood samples were collected in tubes without EDTA. Serum levels of visfatin and ghrelin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program and differences were considered statistically significant at p < 0.05. Serum levels of visfatin and ghrelin were significantly higher in asthma group (respectively; p = 0.001, p = 0.002). While visfatin has a pro-inflammatory role, ghrelin exerts an anti-inflammatory effect in asthma. Therefore, visfatin can be a forthcoming biomarker and ghrelin may be a new anti-inflammatory drug target to diagnose and treat asthmatic patients.